David Wages
Overview
Explore the profile of David Wages including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, et al.
Clin Cancer Res
. 2020 Aug;
26(22):5830-5842.
PMID: 32816889
Purpose: Y-FF-21101 is an Yttrium-90-conjugated, chimeric mAb that is highly specific for binding to human placental (P)-cadherin, a cell-to-cell adhesion molecule overexpressed and associated with cancer invasion and metastatic dissemination...
2.
Smith D, Conkling P, Richards D, Nemunaitis J, Boyd T, Mita A, et al.
Cancer Immunol Immunother
. 2014 Apr;
63(8):787-96.
PMID: 24770667
Background: IMO-2055 is a Toll-like receptor 9 (TLR9) agonist that potentially enhances the efficacy of antitumor agents through immune stimulation. The objective of this phase Ib dose-escalation trial (3 +...
3.
Wu Y, Park K, Soo R, Sun Y, Tyroller K, Wages D, et al.
BMC Cancer
. 2011 Oct;
11:430.
PMID: 21982342
Background: Previous research suggests the therapeutic cancer vaccine L-BLP25 potentially provides a survival benefit in patients with locally advanced unresectable stage III non-small cell lung carcinoma (NSCLC). These promising findings...
4.
Rios J, Hambleton J, Viele M, Rugg N, Sindermann G, Greenwalt T, et al.
Transfusion
. 2006 Sep;
46(10):1778-86.
PMID: 17002635
Background: A nucleic acid-targeted pathogen inactivation process with S-303 was developed to treat red blood cells (RBCs). Study Design And Methods: Three studies in healthy subjects investigated posttransfusion recovery, life...
5.
Melnikova I, Wages D
Nat Rev Drug Discov
. 2006 Jun;
5(5):369-70.
PMID: 16802443
No abstract available.
6.
Mintz P, Bass N, Petz L, Steadman R, Streiff M, McCullough J, et al.
Blood
. 2006 Jan;
107(9):3753-60.
PMID: 16410447
An ex vivo photochemical treatment (PCT) process was developed to inactivate pathogens in fresh frozen plasma (PCT-FFP). A prospective, controlled, double-blinded, randomized study was conducted to evaluate the efficacy and...
7.
Benjamin R, McCullough J, Mintz P, Snyder E, Spotnitz W, Rizzo R, et al.
Transfusion
. 2005 Nov;
45(11):1739-49.
PMID: 16271099
Background: A randomized, double-blind trial is reported of the clinical efficacy of red blood cells (RBCs) treated for pathogen inactivation with S-303, a synthetic labile alkylating agent. Study Design And...
8.
de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, et al.
Transfusion
. 2005 Aug;
45(8):1362-72.
PMID: 16078927
Background: Photochemical treatment (PCT) with amotosalen HCl (S-59) was developed to inactivate pathogens and white blood cells in plasma (PCT-FFP) used for transfusion support. Study Design And Methods: An open-label,...
9.
Maloney Jr C, Wages D, Upton J, Lee W
Plast Reconstr Surg
. 2003 Apr;
111(6):1899-904.
PMID: 12711950
Microvascular transfer of the omentum has several unique advantages for the reconstruction and revascularization of extremity wounds. The omentum provides well-vascularized, malleable tissue for reconstruction of extensive soft-tissue defects and...
10.
Hambleton J, Wages D, Radu-Radulescu L, Adams M, Mackenzie M, Shafer S, et al.
Transfusion
. 2002 Nov;
42(10):1302-7.
PMID: 12423514
Background: To date, no clinical trials have characterized FFP infusion efficacy, and infusion still carries infectious risk. This single-blinded crossover study compared postinfusion kinetics of FVII in photochemically treated FFP...